Mn Services Vermogensbeheer B.V. Increases Holdings in Alexion Pharmaceuticals, Inc. (ALXN)

Mn Services Vermogensbeheer B.V. raised its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 1.3% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 38,355 shares of the biopharmaceutical company’s stock after buying an additional 500 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in Alexion Pharmaceuticals were worth $5,185,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in ALXN. Investors Research Corp acquired a new stake in shares of Alexion Pharmaceuticals during the 1st quarter worth approximately $27,000. Captrust Financial Advisors bought a new position in Alexion Pharmaceuticals in the 4th quarter worth approximately $31,000. Whittier Trust Co. grew its holdings in Alexion Pharmaceuticals by 20.4% in the 1st quarter. Whittier Trust Co. now owns 472 shares of the biopharmaceutical company’s stock worth $64,000 after buying an additional 80 shares in the last quarter. NuWave Investment Management LLC grew its holdings in Alexion Pharmaceuticals by 851.9% in the 4th quarter. NuWave Investment Management LLC now owns 514 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 460 shares in the last quarter. Finally, Prime Capital Investment Advisors LLC bought a new position in Alexion Pharmaceuticals in the 1st quarter worth approximately $74,000. Hedge funds and other institutional investors own 94.82% of the company’s stock.

A number of equities analysts recently issued reports on ALXN shares. Credit Suisse Group reissued a “buy” rating and issued a $156.00 price objective on shares of Alexion Pharmaceuticals in a report on Tuesday, January 22nd. BidaskClub raised Alexion Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, January 22nd. Morgan Stanley increased their price objective on Alexion Pharmaceuticals from $165.00 to $175.00 and gave the stock an “overweight” rating in a report on Tuesday, February 12th. Zacks Investment Research lowered Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, February 12th. Finally, Guggenheim started coverage on Alexion Pharmaceuticals in a report on Friday, February 22nd. They issued a “neutral” rating and a $135.00 price objective for the company. Six analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $162.25.

Shares of NASDAQ ALXN opened at $131.40 on Friday. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.87 and a quick ratio of 3.36. The firm has a market cap of $28.79 billion, a price-to-earnings ratio of 18.53, a PEG ratio of 1.01 and a beta of 1.53. Alexion Pharmaceuticals, Inc. has a 1 year low of $92.56 and a 1 year high of $141.86.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.40. The firm had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.13 billion. Alexion Pharmaceuticals had a return on equity of 19.53% and a net margin of 9.59%. The firm’s quarterly revenue was up 22.5% on a year-over-year basis. During the same period last year, the company posted $1.68 EPS. Equities research analysts forecast that Alexion Pharmaceuticals, Inc. will post 8.6 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Mn Services Vermogensbeheer B.V. Increases Holdings in Alexion Pharmaceuticals, Inc. (ALXN)” was originally published by Stock Observer and is owned by of Stock Observer. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.thestockobserver.com/2019/05/17/mn-services-vermogensbeheer-b-v-increases-holdings-in-alexion-pharmaceuticals-inc-alxn.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Featured Story: How to Trade Using Analysts Ratings

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.